Testing two drug plans for HER2 positive breast cancer that has spread to the brain
Original title: T-DXd With or Without Neratinib for HER2 Positive Breast Cancer With Brain Metastasis
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is a middle stage trial, so the drugs are still being tested in people.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This trial asks if adding a second drug helps when HER2 positive breast cancer reaches the brain.
Who this trial is for. This trial is for people with HER2 positive breast cancer that has spread to the brain. It tests the drug trastuzumab deruxtecan, also called T-DXd, given alone or together with a drug called neratinib.
Where it stands. The trial has not reported results. It is looking at how well each drug plan works and how safe it is. Patients are placed into the two groups at random. The answer is not in yet.
What this means, and what it doesn't
What it could mean: Someone with HER2 positive breast cancer that has spread to the brain might ask their care team about this trial. The care team can say if it is worth looking into. They can also explain what taking part would involve.
What it doesn't mean: This does not mean these drugs are proven to work better together. A trial is a test, not a treatment your doctor can simply give you. Joining a trial is not a promise that you will be helped. This is not a promise of a cure.
Source: ClinicalTrials.gov, September 28, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.